Summit Therapeutics Analyst Price Targets - Benzinga

Summit Therapeutics Inc

SMMTNASDAQ

Trade with Public

Trade with Public

$15.23

-0.29-1.87%

마지막 업데이트: Oct 14, 1:56 PM

$15.37

-0.15-0.95%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Summit Therapeutics Analyst Price Targets - Benzinga

Summit Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Summit Therapeutics (SMMT).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

3S.Buy

10Buy

4Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$32Upside to Avg. PT+109.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Barclays	Etzer Darout	PT Raise	Equal-Weight	$18→$20
Sep 29, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$40→$43
Sep 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Sep 9, 2026	Jefferies	Faisal Khurshid	Upgrade	Hold→Buy	$15→$25
Aug 26, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Aug 25, 2026	Bernstein	Jeffrey Walch	Upgrade	Underperform→Market Perform	$10→$12
Aug 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Aug 12, 2026	Leerink Partners	Daina Graybosch	Upgrade	Underperform→Market Perform	$12→$13
Jul 24, 2026	Stifel	Dara Azar	PT Cut	Buy	$45→$38
Jul 24, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$40→$38
Jul 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
May 22, 2026	Bernstein	Jeffrey Walch	Initiate	Underperform	$8
May 22, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
May 4, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$30→$23
May 1, 2026	Piper Sandler	Kelsey Goodwin	PT Cut	Neutral	$17→$16
Apr 8, 2026	Stifel	Dara Azar	Initiate	Buy	$45
Mar 16, 2026	Jefferies	Clara Dong	Downgrade	Buy→Hold	$42→$15
Feb 24, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$40→$30
Feb 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$40
Jan 30, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20

Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $40 to $43.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.

Benzinga Newsdesk

PRO
Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25

Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.

Benzinga Newsdesk

This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top analysts upgraded Fluence Energy, Dynatrace, and Advanced Micro Devices, Check out their ratings.

Avi Kapoor